ANI PHARMACEUTICALS INC (ANIP) Fundamental Analysis & Valuation

NASDAQ:ANIP • US00182C1036

Current stock price

78.36 USD
-1.78 (-2.22%)
At close:
78.36 USD
0 (0%)
After Hours:

This ANIP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. ANIP Profitability Analysis

1.1 Basic Checks

  • ANIP had positive earnings in the past year.
  • In the past year ANIP had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: ANIP reported negative net income in multiple years.
  • Of the past 5 years ANIP 4 years had a positive operating cash flow.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • ANIP has a Return On Assets of 4.87%. This is amongst the best in the industry. ANIP outperforms 85.42% of its industry peers.
  • Looking at the Return On Equity, with a value of 12.98%, ANIP belongs to the top of the industry, outperforming 88.02% of the companies in the same industry.
  • ANIP has a better Return On Invested Capital (7.97%) than 87.50% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ANIP is significantly below the industry average of 13.06%.
  • The 3 year average ROIC (4.79%) for ANIP is below the current ROIC(7.97%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.87%
ROE 12.98%
ROIC 7.97%
ROA(3y)1.67%
ROA(5y)-1.41%
ROE(3y)3.89%
ROE(5y)-2.98%
ROIC(3y)4.79%
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 10 -10

1.3 Margins

  • ANIP's Profit Margin of 7.95% is amongst the best of the industry. ANIP outperforms 83.33% of its industry peers.
  • ANIP has a Operating Margin of 12.83%. This is amongst the best in the industry. ANIP outperforms 84.38% of its industry peers.
  • ANIP has a better Gross Margin (61.36%) than 70.31% of its industry peers.
  • ANIP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.83%
PM (TTM) 7.95%
GM 61.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.01%
GM growth 5Y1.07%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. ANIP Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ANIP is destroying value.
  • ANIP has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ANIP has more shares outstanding
  • The debt/assets ratio for ANIP has been reduced compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

2.2 Solvency

  • An Altman-Z score of 2.44 indicates that ANIP is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • ANIP has a Altman-Z score of 2.44. This is in the better half of the industry: ANIP outperforms 64.58% of its industry peers.
  • The Debt to FCF ratio of ANIP is 3.60, which is a good value as it means it would take ANIP, 3.60 years of fcf income to pay off all of its debts.
  • ANIP's Debt to FCF ratio of 3.60 is amongst the best of the industry. ANIP outperforms 88.54% of its industry peers.
  • A Debt/Equity ratio of 1.11 is on the high side and indicates that ANIP has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.11, ANIP is doing worse than 73.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 3.6
Altman-Z 2.44
ROIC/WACC0.91
WACC8.75%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • ANIP has a Current Ratio of 2.71. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
  • ANIP has a Current ratio of 2.71. This is comparable to the rest of the industry: ANIP outperforms 46.88% of its industry peers.
  • A Quick Ratio of 2.19 indicates that ANIP has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.19, ANIP is in line with its industry, outperforming 49.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.19
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. ANIP Growth Analysis

3.1 Past

  • ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.35%, which is quite impressive.
  • ANIP shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 17.59% yearly.
  • ANIP shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 17.50%.
  • The Revenue has been growing by 33.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)51.35%
EPS 3Y77.39%
EPS 5Y17.59%
EPS Q2Q%42.94%
Revenue 1Y (TTM)17.5%
Revenue growth 3Y40.81%
Revenue growth 5Y33.48%
Sales Q2Q%29.64%

3.2 Future

  • ANIP is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.75% yearly.
  • The Revenue is expected to grow by 11.49% on average over the next years. This is quite good.
EPS Next Y15.55%
EPS Next 2Y17.27%
EPS Next 3Y14.38%
EPS Next 5Y11.75%
Revenue Next Year20.75%
Revenue Next 2Y19.16%
Revenue Next 3Y16.28%
Revenue Next 5Y11.49%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10

More info and screens

Find the best growth stocksShow best growing peers

9

4. ANIP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.96, which indicates a very decent valuation of ANIP.
  • Based on the Price/Earnings ratio, ANIP is valued cheaper than 91.67% of the companies in the same industry.
  • ANIP's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.78.
  • With a Price/Forward Earnings ratio of 8.62, the valuation of ANIP can be described as very reasonable.
  • 90.63% of the companies in the same industry are more expensive than ANIP, based on the Price/Forward Earnings ratio.
  • ANIP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.54, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.96
Fwd PE 8.62
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ANIP is valued cheaper than 87.50% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, ANIP is valued cheaply inside the industry as 89.58% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 10.25
EV/EBITDA 10.3
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ANIP has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ANIP's earnings are expected to grow with 14.38% in the coming years.
PEG (NY)0.64
PEG (5Y)0.57
EPS Next 2Y17.27%
EPS Next 3Y14.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ANIP Dividend Analysis

5.1 Amount

  • No dividends for ANIP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ANIP Fundamentals: All Metrics, Ratios and Statistics

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (4/10/2026, 8:06:07 PM)

After market: 78.36 0 (0%)

78.36

-1.78 (-2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-27
Earnings (Next)05-08
Inst Owners96.9%
Inst Owner Change0%
Ins Owners6.72%
Ins Owner Change-1.16%
Market Cap1.76B
Revenue(TTM)883.37M
Net Income(TTM)70.21M
Analysts84.29
Price Target112.2 (43.19%)
Short Float %18.84%
Short Ratio9.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP1.65%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.26%
Min EPS beat(2)14.04%
Max EPS beat(2)14.48%
EPS beat(4)4
Avg EPS beat(4)18.34%
Min EPS beat(4)14.04%
Max EPS beat(4)24.28%
EPS beat(8)8
Avg EPS beat(8)16.26%
EPS beat(12)12
Avg EPS beat(12)41.92%
EPS beat(16)14
Avg EPS beat(16)16.21%
Revenue beat(2)2
Avg Revenue beat(2)5.22%
Min Revenue beat(2)4.62%
Max Revenue beat(2)5.83%
Revenue beat(4)4
Avg Revenue beat(4)6.58%
Min Revenue beat(4)4.62%
Max Revenue beat(4)8.9%
Revenue beat(8)8
Avg Revenue beat(8)5.67%
Revenue beat(12)12
Avg Revenue beat(12)8.97%
Revenue beat(16)15
Avg Revenue beat(16)7.35%
PT rev (1m)0.26%
PT rev (3m)1.45%
EPS NQ rev (1m)-7.17%
EPS NQ rev (3m)-5.68%
EPS NY rev (1m)0%
EPS NY rev (3m)6.26%
Revenue NQ rev (1m)1.29%
Revenue NQ rev (3m)5.25%
Revenue NY rev (1m)0.94%
Revenue NY rev (3m)10.74%
Valuation
Industry RankSector Rank
PE 9.96
Fwd PE 8.62
P/S 1.99
P/FCF 10.25
P/OCF 9.48
P/B 3.25
P/tB N/A
EV/EBITDA 10.3
EPS(TTM)7.87
EY10.04%
EPS(NY)9.09
Fwd EY11.61%
FCF(TTM)7.64
FCFY9.76%
OCF(TTM)8.26
OCFY10.54%
SpS39.4
BVpS24.12
TBVpS-0.06
PEG (NY)0.64
PEG (5Y)0.57
Graham Number65.35
Profitability
Industry RankSector Rank
ROA 4.87%
ROE 12.98%
ROCE 9.75%
ROIC 7.97%
ROICexc 10.68%
ROICexgc 28.47%
OM 12.83%
PM (TTM) 7.95%
GM 61.36%
FCFM 19.4%
ROA(3y)1.67%
ROA(5y)-1.41%
ROE(3y)3.89%
ROE(5y)-2.98%
ROIC(3y)4.79%
ROIC(5y)N/A
ROICexc(3y)6.47%
ROICexc(5y)N/A
ROICexgc(3y)15.17%
ROICexgc(5y)N/A
ROCE(3y)5.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.01%
GM growth 5Y1.07%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF 3.6
Debt/EBITDA 2.93
Cap/Depr 15.13%
Cap/Sales 1.57%
Interest Coverage 4.21
Cash Conversion 90.46%
Profit Quality 244.11%
Current Ratio 2.71
Quick Ratio 2.19
Altman-Z 2.44
F-Score7
WACC8.75%
ROIC/WACC0.91
Cap/Depr(3y)17.98%
Cap/Depr(5y)14.85%
Cap/Sales(3y)2.01%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.35%
EPS 3Y77.39%
EPS 5Y17.59%
EPS Q2Q%42.94%
EPS Next Y15.55%
EPS Next 2Y17.27%
EPS Next 3Y14.38%
EPS Next 5Y11.75%
Revenue 1Y (TTM)17.5%
Revenue growth 3Y40.81%
Revenue growth 5Y33.48%
Sales Q2Q%29.64%
Revenue Next Year20.75%
Revenue Next 2Y19.16%
Revenue Next 3Y16.28%
Revenue Next 5Y11.49%
EBIT growth 1Y536.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.6%
EBIT Next 3Y16.15%
EBIT Next 5Y16.95%
FCF growth 1Y258.7%
FCF growth 3YN/A
FCF growth 5Y79.76%
OCF growth 1Y189.34%
OCF growth 3YN/A
OCF growth 5Y64.73%

ANI PHARMACEUTICALS INC / ANIP Fundamental Analysis FAQ

What is the fundamental rating for ANIP stock?

ChartMill assigns a fundamental rating of 6 / 10 to ANIP.


Can you provide the valuation status for ANI PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 9 / 10 to ANI PHARMACEUTICALS INC (ANIP). This can be considered as Undervalued.


What is the profitability of ANIP stock?

ANI PHARMACEUTICALS INC (ANIP) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for ANIP stock?

The Price/Earnings (PE) ratio for ANI PHARMACEUTICALS INC (ANIP) is 9.96 and the Price/Book (PB) ratio is 3.25.


What is the earnings growth outlook for ANI PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ANI PHARMACEUTICALS INC (ANIP) is expected to grow by 15.55% in the next year.